290650.KQ
L&C Bio Co., Ltd
KOE · Healthcare · Medical - Specialties · KR
KRW 48,600.00
−10.00%Year over year
Reported trailing growth
- Revenue
- +53.1%
- EBITDA
- -89.0%
- EBIT
- +1825.9%
- EPS
- —
- Free cash flow
- +36.3%
- Operating cash flow
- +3235.2%
Forward estimates
Based on analyst estimates
- Revenue
- +58.6%
- EBITDA
- +241.2%
- EPS
- +122.4%
Three-year CAGR
- Revenue
- +17.6%
- EBITDA
- -6.7%
- EBIT
- -28.7%
- Net income
- —
- EPS
- —
- Free cash flow
- +76.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026